Intravenous methylprednisolone pulse therapy for acute posterior segment uveitis attacks in Behçet's disease.
We evaluated the efficacy and safety of high-dose intravenous methylprednisolone (1 g x 3 days) pulse therapy followed in the management of acute posterior segment uveitis attacks in 25 patients with Behçet's disease. High-dose intravenous methylprednisolone pulse therapy may be beneficial in the prompt control of severe ocular inflammation and in preventing visual loss.
Yalçindag
F Nilûfer
FN
Department of Ophthalmology, Ankara University Medical School, Ankara, Turkey. yalcinda@medicine.Ankara.edu.tr
Can
Ertugrul
E
Ozdemir
Ozden
O
D000208:Acute Disease; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000150:complications*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002386:Cataract / Q000139:chemically induced; D005260:Female; D005483:Flushing / Q000139:chemically induced; D005500:Follow-Up Studies; D005901:Glaucoma / Q000139:chemically induced; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D020551:Pulse Therapy, Drug; D012164:Retinal Diseases / Q000139:chemically induced; D012189:Retrospective Studies; D016896:Treatment Outcome; D015866:Uveitis, Posterior / Q000188:drug therapy* / Q000209:etiology*; D015430:Weight Gain
D000893:Anti-Inflammatory Agents; D001786:Blood Glucose; D008775:Methylprednisolone